2022
Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation
2010
Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder
Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology 2010, 213: 547-553. PMID: 20480149, PMCID: PMC3139174, DOI: 10.1007/s00213-010-1881-0.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMajor depressive episodeDepressive disorderPositron emission tomography scanningCurrent major depressive episodeHealthy control groupSpecific receptor subtypesHealthy control participantsHeteroreceptor functionMethodsTen participantsSerotonin1B receptorsAntidepressant actionΓ-amino butyric acidDepressive episodeGlutamate systemReceptor subtypesVentral pallidumNucleus accumbensDepressive phenotypeReceptor radioligandTherapeutic rationaleMDD groupControl groupDysfunctional rewardTomography scanning